Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

e

NPS reported net income of $14.1 million for the third quarter of 2007 and ended the quarter with $302.2 million in cash and marketable securities. During the third quarter the following financial transactions were executed:

-- NPS granted Nycomed the rights to develop and market GATTEX outside

North America, which generated an up-front payment of $10 million;

-- NPS sold $11 million of Preotact(R) bulk drug supply to Nycomed;

-- The Preotact royalty entitlement was sold to Drug Royalty LP 3 for an

up-front payment of $50 million;

-- $50 million of convertible notes were issued to Visium Asset

Management;

-- $100 million in Sensipar(R) royalty-backed notes were issued;

-- $20.2 million of 3% Convertible Notes were repurchased for $19.5

million.

Subsequent to the close of the third quarter the following transactions were completed:

-- NPS sold its interests in the mGluR research and development program

to partner AstraZeneca for $30 million;

-- $171.2 million of its outstanding 3% Convertible Notes were repurchased

through a cash tender offer for $169.1 million;

-- Nycomed elected to proceed with the GATTEX licensing agreement,

triggering a $25 million additional upfront payment to NPS.

Excluding the net proceeds generated by new business development activities and financing transactions executed in 2007, NPS now expects to have a 2007 cash burn between $70 and $80 million, a change from its earlier guidance of $80 to $90 million. As a result of the reduced cash burn, recent transactions and gains on facilities sales, NPS is revising its previous year end cash balance guidance of $65 to $75 million to a new range of between $130 and $140 million.

NPS projects that its 2008 cash burn will be $35 to 45 million, as indicated in previous guidance. With the reduced cash burn and revised cash balance, NPS should have sufficient cash
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at the ... University , and funded by the Jeffrey Epstein VI ... tumors can be visually identified for elimination. These aggressive cells ... study, which shows a topological map of what to look ... cancer research, for while tumor cells can be extracted from ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... elected mayor of Colorados largest city, businessman John Hickenlooper invited ... was to ceremoniously bury the hatchet of intra-regional rivalry and ... metropolitan area, or not at all. , ,Every suburban ... a near-unanimous effort to pass a $4.7-billion mass transit initiative ...
... data quality firm Firstlogic for about $69 million ... second quarter. , ,Firstlogic is a privately held firm that ... sure their data is as correct as they need to ... call centers, web sites, customer relationship management systems, and business ...
... settled with a Belgian company that sued last September ... virus genotyping technology from Innogenetics, for undisclosed financial terms. ... Aril 2004 Third Wave forged a deal under which ... line of products in Europe. It was Third Wave's ...
Cached Biology Technology:Economic collaboration in Denver sets tall goal for Wisconsin 2Economic collaboration in Denver sets tall goal for Wisconsin 3
(Date:8/20/2014)... Oklahoma Medical Research Foundation a five-year, $14.5 million grant ... effects on humans. , For 10 years, OMRF ... the human immune response to anthrax bacteria as part ... funding came soon after anthrax-laced letters killed five and ... of Sept. 11, 2001. , The long-term goal ...
(Date:8/20/2014)... athletes who have suffered concussions ready to return to ... that high school athletes who head back on the ... significant regression in their abilities to simultaneously walk and ... in changes in their balance and/or altered walking speed, ... the 12 had returned to activity in less than ...
(Date:8/20/2014)... Biting into a chili pepper causes a burning spiciness ... Scientists exploring the chili pepper,s effect are using their ... kinds of pain, which can be caused by inflammation ... compound, which is being tested in clinical trials, in ... Tafesse and colleagues explain that decades ago, scientists had ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... March 30, 2012 The Phoenix Community Alliance (PCA) ... Genomics Research Institute (TGen), with its most prestigious award. ... City Starr Award for his work in improving the ... studying diseases such as Alzheimer,s, diabetes and many types ...
... FL, March 30, 2012 The National Institutes of Health ... the role of a pathway in the development and maintenance ... immune system and turns normal disease fighting cells into cancers. ... part of our white blood cells. John Cleveland, ...
... Bethesda, MD FASEB MARC (Maximizing Access to ... for the 2012 American Society for Clinical Investigation/Association of ... April 27-29, 2012. These awards are meant to ... scientists into the mainstream of the basic science community ...
Cached Biology News:Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2Scientists win $2 million to study new pathway in development and maintenance of lymphoma 2